

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6924931

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	THE ASAN FOUNDATION	08/10/2021
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	ONCONIC THERAPEUTICS INC.	
<b>Street Address:</b>	11F, 12 TEHERAN-RO 26-GIL	
<b>Internal Address:</b>	GANGNAM-GU	
<b>City:</b>	SEOUL	
<b>State/Country:</b>	KOREA, REPUBLIC OF	
<b>Postal Code:</b>	05855	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Patent Number:	10683553
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(314)612-2307	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	3146215070	
<b>Email:</b>	uspatents@armstrongteasdale.com	
<b>Correspondent Name:</b>	PATENT DOCKETING DEPARTMENT	
<b>Address Line 1:</b>	7700 FORSYTH BLVD.	
<b>Address Line 2:</b>	SUITE 1800	
<b>Address Line 4:</b>	ST. LOUIS, MISSOURI 63105	
<b>ATTORNEY DOCKET NUMBER:</b>	42230-6	
<b>NAME OF SUBMITTER:</b>	KELLY A. ECHOLS	
<b>SIGNATURE:</b>	/Kelly A. Echols/	
<b>DATE SIGNED:</b>	09/20/2021	
<b>Total Attachments: 3</b>		
source=Assignment(executed)US15742408_US10683553-42833816#page1.tif		
source=Assignment(executed)US15742408_US10683553-42833816#page2.tif		
source=Assignment(executed)US15742408_US10683553-42833816#page3.tif		

## ASSIGNMENT

This Agreement is by and between: **THE ASAN FOUNDATION**, having a principal place of business at 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea ("ASSIGNOR"); and **ONCONIC THERAPEUTICS INC.**, having a principal place of business at 11F, 12 Teheran-ro 26-gil, Gangnam-gu, Seoul, Republic of Korea 06236 ("ASSIGNEE").

In consideration of good and valuable consideration, the receipt of which is hereby acknowledged, Assignor hereby sell, assign, and transfer to Assignee and its successors, assigns, and legal representatives, the entire right, title, and interest for the United States and all other countries, in and to any and all inventions and improvements that are disclosed in the application for the patent entitled: METHOD FOR DETERMINING SENSITIVITY TO SIMULTANEOUS INHIBITOR AGAINST PARP AND TANKYRASE, Serial No. 15/742,408, filed January 5, 2018, now Patent No. 10,683,553, issued June 16, 2020, assigned Attorney Docket No. 59642-104; and

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR, hereby assigns and transfers to ASSIGNEE the full and exclusive right, title, and interest in and to said inventions, said patent application, and any and all patent rights and letters patent for said inventions in the United States of America and elsewhere throughout the world, including provisional rights, foreign patent priority rights, right to claim priority to said patent application in any international patent application, and the right to apply for patents in ASSIGNOR's name or in the name of ASSIGNEE and further including all divisions and continuations of said application and of any foreign patent application, and all reissues and extensions of patent rights and letters patent for said inventions, all to be held and enjoyed by ASSIGNEE for its own use and benefit, and by its successors and assigns for their own use and benefit, for the full duration of the terms for which patent rights and letters patent may be granted in this or any foreign country, and covenants that ASSIGNOR has full right so to do, and agrees that ASSIGNOR will communicate to ASSIGNEE and its successors and assigns, any facts known to ASSIGNOR respecting said inventions, and testify in any legal proceeding, sign all lawful papers, execute all lawful divisional, continuation, and reissue application, make all rightful declarations or oaths, and do everything lawfully possible to aid ASSIGNEE and its successors and assigns, to obtain and enforce proper patent protection for said inventions in the United States of America and elsewhere throughout the world.

This Assignment is effective as of the respective filing date set forth above.

111487062,1 0059642-00104

Executed at Seoul, Republic of Korea this 10<sup>th</sup> day of

August, 2021.



Name: Jieun KIM


Title: (In-house) Patent Attorney, Director

THE ASAN FOUNDATION

88, Olympic-ro 43-gil, Songpa-gu,  
Seoul 05505, Republic of Korea

Executed at Seoul, Republic of Korea, this 10th day of

August, 2021.



Name: John Kim

Title: CEO

ONCONIC THERAPEUTICS INC.  
11F, 12 Teheran-ro 26-gil, Gangnam-gu  
Seoul, Republic of Korea 05855